Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Total Non-Current Liabilities (2020 - 2025)

Treace Medical Concepts' Total Non-Current Liabilities history spans 6 years, with the latest figure at $100.2 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 3.75% year-over-year to $100.2 million; the TTM value through Dec 2025 reached $100.2 million, down 3.75%, while the annual FY2025 figure was $100.2 million, 3.75% down from the prior year.
  • Total Non-Current Liabilities reached $100.2 million in Q4 2025 per TMCI's latest filing, down from $107.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $116.2 million in Q1 2024 to a low of $37.8 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $88.5 million, with a median of $99.9 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: surged 135.35% in 2022, then decreased 13.52% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $47.6 million in 2021, then skyrocketed by 107.03% to $98.5 million in 2022, then increased by 15.67% to $113.9 million in 2023, then decreased by 8.63% to $104.1 million in 2024, then dropped by 3.75% to $100.2 million in 2025.
  • Per Business Quant, the three most recent readings for TMCI's Total Non-Current Liabilities are $100.2 million (Q4 2025), $107.4 million (Q3 2025), and $108.7 million (Q2 2025).